用于戒烟的洛贝林。
Lobeline for smoking cessation.
作者信息
Stead Lindsay F, Hughes John R
机构信息
Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
出版信息
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD000124. doi: 10.1002/14651858.CD000124.pub2.
BACKGROUND
Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.
OBJECTIVES
The objective of this review was to assess the effects of lobeline on long term smoking cessation.
SEARCH METHODS
We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011).
SELECTION CRITERIA
Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.
DATA COLLECTION AND ANALYSIS
We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.
MAIN RESULTS
We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence.
AUTHORS' CONCLUSIONS: There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.
背景
洛贝林是一种部分尼古丁激动剂，已被用于多种市售制剂中以帮助戒烟。
目的
本综述的目的是评估洛贝林对长期戒烟的影响。
检索方法
我们检索了Cochrane烟草成瘾小组试验注册库（最近一次检索时间为2011年12月）。
入选标准
将洛贝林与安慰剂或其他治疗对照进行比较的随机试验，这些试验报告了至少随访六个月的戒烟情况。
数据收集与分析
我们对受试者类型、洛贝林的剂量和剂型、结局指标、随机化方法以及随访完整性进行了重复数据提取。
主要结果
我们未找到符合包括长期随访在内的全部纳入标准的试验。一项大型试验未发现对短期戒烟有任何影响。
作者结论
长期试验没有证据表明洛贝林有助于戒烟，短期证据表明其没有益处。
Zotero 插件